Boehringer Ingelheim Sued For €23M Over Diabetes Drug IP
Biopharmaceutical licensing company Royalty Pharma has sued Boehringer Ingelheim in a U.K. court, saying the German drug giant reneged on a 2015 deal by unilaterally reducing the patent royalties it paid...To view the full article, register now.
Already a subscriber? Click here to view full article